Αναζήτηση Δραστικών

TENECTEPLASE

ATC

Εμπορικές Ονομασίες

  • DRUGBANK - Tenecteplase
  • indication:

    For treatment of myocardial infarction and lysis of intracoronary emboli

  • pharmacology:

  • mechanism:

    Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

  • toxicity:

  • absorprion:

  • halflife:

    1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo)

  • roouteelimination:

  • volumedistribution:

  • clearance:

    * 99 - 119 mL/min [acute myocardial infarction patients]